A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

Trial Details

NCT ID

NCT07325136

Phase

PHASE1 / PHASE2

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• BMS-986525
• Pumitamig

Locations (sample)

• Detroit, Michigan, United States|42.33143,-83.04575
• Buffalo, New York, United States|42.88645,-78.87837
• Durham, North Carolina, United States|35.99403,-78.89862
• Cleveland, Ohio, United States|41.4995,-81.69541
• Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

• Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC).
• Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.
• In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therap…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.